Human serum albumin
Human serum albumin (HSA) is the principal albumin-associated protein considered in the supplied biomedical literature.
Human serum albumin (HSA) is the principal albumin-associated protein considered in the supplied biomedical literature. Its capacity to bind diverse molecular partners gives it roles in drug complexation, pharmacokinetics, biodistribution, and the design of therapeutic and diagnostic systems. The cited studies examine HSA as a binding partner for small molecules, radiolabeled ligands, and engineered proteins; as a component of half-life-extension strategies; and as a biomaterial for hydrogel formation.
The recent work represents the broad Protein Applications theme rather than a single convergent biological question. Applications include cancer-targeting agents, cytotoxicity and tumor retention, albumin-mediated pharmacokinetic control, protein-derived hydrogels, and analytical measurement of serum albumin. Related systems involve binding to teicoplanin, mitoxantrone, gallium-labeled fibroblast activation protein inhibitors, and radiolabeled ligands directed against PSMA and GRPR, as well as fusion to coagulation factor IX and association with engineered single-domain proteins.
Where the papers sit
12 papers from the last 6 months study human serum albumin directly · updated from PubMed 10 Nov 2026
Study type 1 clinical trial · 5 human data · 6 preclinical
Themes one subject · 1 new direction
Those 12 are all about one subject.
-
Albumin-Based Biomedicine
Albumin serves as a carrier, half-life extender, biomaterial, and therapeutic adjunct across drug delivery, radiotracers, clotting factors, hydrogels, and stroke care. Structural stability, chemical modification, and albumin binding recur as determinants of biodistribution, circulation time, and tissue transport. Applications include Ga(III)-NOTA dendrimers, FAP inhibitors, PSMA/GRPR radioligands, and engineered albumin variants. The set is broad and application-driven, without a single convergent clinical or mechanistic direction.
Human serum albumin becomes a tunable drug-release biomaterial rather than a soluble binding or half-life-extending protein
The human serum albumin-derived hydrogel study uses HSA as the material forming the delivery network, not merely as a soluble binding partner or pharmacokinetic modifier. Reduction-induced partial unfolding drives intermolecular assembly, while cation valency controls gelation, mechanical properties, network density, and doxorubicin release. This assigns HSA a new structural role as a controllable hydrogel scaffold whose architecture directly governs tissue-level drug transport 42314886Jun.
Papers
The 12 papers from the last 6 months that study human serum albumin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Albumin-Based Biomedicine (12)
- Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles. Molecular pharmaceutics · 2 Nov 2026 PMID 42969721
- Structural conservation and expanded functionality of hyper-stable human serum albumin variants. Protein science : a publication of the Protein Society · 28 Oct 2026 PMID 42948893
- Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European stroke journal · 5 Oct 2026 PMID 42831671
- Structure-biodistribution relationships of chemically and physically modified albumin: a systematic approach to organ-specific drug delivery. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777828
- Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein. Molecular pharmaceutics · 7 Sept 2026 PMID 42704121
- Impact of a protein addition on the microstructure and rheological properties of silica hydrogels. Soft matter · 1 Sept 2026 PMID 42676005
- Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics. International journal of pharmaceutics · 18 Jul 2026 PMID 42471168
- Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
- Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood advances · 2 Jul 2026 PMID 42392182
- Ion valency-driven control of network architecture and tissue-level drug transport in protein-derived hydrogels. International journal of biological macromolecules · 18 Jun 2026 PMID 42314886
- Centrifugal microfluidics for rapid target analyte quantification in airborne bioaerosols. Lab on a chip · 18 Jun 2026 PMID 42312931
- Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
By study type
Clinical trials (1)
- Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European stroke journal · 5 Oct 2026 PMID 42831671
Human data, design not indexed (5)
- Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles. Molecular pharmaceutics · 2 Nov 2026 PMID 42969721
- Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics. International journal of pharmaceutics · 18 Jul 2026 PMID 42471168
- Ion valency-driven control of network architecture and tissue-level drug transport in protein-derived hydrogels. International journal of biological macromolecules · 18 Jun 2026 PMID 42314886
- Centrifugal microfluidics for rapid target analyte quantification in airborne bioaerosols. Lab on a chip · 18 Jun 2026 PMID 42312931
- Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
Preclinical: animal, cell and lab studies (6)
- Structural conservation and expanded functionality of hyper-stable human serum albumin variants. Protein science : a publication of the Protein Society · 28 Oct 2026 PMID 42948893
- Structure-biodistribution relationships of chemically and physically modified albumin: a systematic approach to organ-specific drug delivery. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777828
- Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein. Molecular pharmaceutics · 7 Sept 2026 PMID 42704121
- Impact of a protein addition on the microstructure and rheological properties of silica hydrogels. Soft matter · 1 Sept 2026 PMID 42676005
- Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
- Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood advances · 2 Jul 2026 PMID 42392182
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-09-21. Drafted by language models from published abstracts; not medical advice.